Antagonism of cytotoxic T-lymphocyte activation by soluble CD8

Nature Medicine

Volumn 5, Issue 4, 1999, Pages 399-404

  Sewell, Andrew K ^a   Gerth, Ulrich C ^a   Price, David A ^a   Purbhoo, Marco A ^a   Boulter, Jonathan M ^a   Gao, George F ^a   Bell, John I ^a   Phillips, Rodney E ^a   Jakobsen, Bent K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD3; ANTIGENS, CD8; DIMERIZATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; LIGANDS; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MODELS, IMMUNOLOGICAL; PEPTIDES; PHOSPHORYLATION; PROTEIN CONFORMATION; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SOLUBILITY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032903598     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/7398     Document Type: Article

References (54)

1. Townsend, A. & Bodmer, H. Antigen recognition by class I restricted T lymphocytes. Annu. Rev. Immunol. 7, 601-624 (1989).
2. Doherty, P.C. T cells and viral infections. Sr. Med. Bull. 41, 7-14 (1985).
3. Tanaka, K., Yoshioka, T., Bieberich, C. & Jay, C. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu. Rev. Immunol. 6, 359-380 (1988).
4. Mason, D.W. & Morris, P.J. Effector mechanisms in allograft rejection. Annu. Rev. Immunol. 4, 119-145 (1986).
5. Fung Leung, W.P. et al. CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell 65, 443-449 (1991).
6. Fung Leung, W.P. et al. CD8 is needed for positive selection but differentially required for negative selection of T cells during thymic ontogeny. Eur. J. Immunol. 23, 212-216 (1993).
7. Teh, H.S. et al. Participation of CD4 coreceptor molecules in T-cell repertoire selection. Nature 349, 241-243 (1991).
8. Killeen, N., Moriarty, A., Teh, H.S. & Liftman, D.R. Requirement for CD8-major histocompatibility complex class I interaction in positive and negative selection of developing T cells. J. Exp. Med. 176, 89-97 (1992).
9. Zamoyska, R. The CD8 coreceptor revisited: one chain good, two chains better. Immunity 1, 243-246 (1994).
10. Turner, J.M. et al. Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs. Cell 60, 755-765 (1990).
11. Van Oers, N.S. et al. Disruption of CD8-dependent negative and positive selection of thymocytes is correlated with a decreased association between CD8 and the protein tyrosine kinase, p56lck. Eur. J. Immunol. 22, 735-743 (1992).
12. Anel, A., O'Rourke, A.M., Kleinfeld, A.M. & Mescher, M.F. T cell receptor and CD8-dependent tyrosine phosphorylation events in cytotoxic T lymphocytes: activation of p56lck by CD8 binding to class I protein. Eur. J. Immunol. 26, 2310-2319 (1996).
13. Kersh, E.N., Shaw, A.S. & Allen, P.M. Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation. Science 281, 572-575 (1998).
14. Kwan Lim, G.E., Ong, T., Aosai, F., Stauss, H. & Zamoyska, R. Is CD8 dependence a true reflection of TCR affinity for antigen? Int. Immunol. 5, 1219-1228 (1993).
15. Yoon, S.T., Dianzani, U., Bottomly, K. & Janeway, C.A., Jr. Both high and low avidity antibodies to the T cell receptor can have agonist or antagonist activity. Immunity 1, 563-569 (1994).
16. Glaichenhaus, N., Shastri, N., Littman, D.R. & Turner, J.M. Requirement for association of p56lck with CD4 in antigen-specific signal transduction in T cells. Cell 64, 511-520 (1991).
17. Williams, O., Vukmanovic, S. & Zamoyska, R. Phosphorylation of murine CD8 alpha is not essential for responses of T cell hybridomas to antigen. Int. Immunol. 3, 785-792 (1991).
18. O'Rourke, A.M. & Mescher, M.F. Cytotoxic T-lymphocyte activation involves a cascade of signalling and adhesion events. Nature 358, 253-255 (1992).
19. Chan, I.T. et al. Thymic selection of cytotoxic T cells independent of CD8 alpha-Lck association. Science 261, 1581-1584 (1993).
20. Norment, A.M., Salter, R.D., Parham, P., Engelhard, V.H. & Littman, D.R. Cell-cell adhesion mediated by CD8 and MHC class I molecules. Nature 336, 79-81 (1988).
21. O'Rourke, A.M., Rogers, J. & Mescher, M.F. Activated CD8 binding to class I protein mediated by the T-cell receptor results in signalling. Nature 346, 187-189 (1990).
22. Salter, R.D. et al. A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. Nature 345, 41-46 (1990).
23. Connolly, J.M., Hansen, T.H., Ingold, A.L. & Potter, T.A. Recognition by CD8 on cytotoxic T lymphocytes is ablated by several substitutions in the class I alpha 3 domain: CD8 and the T-cell receptor recognize the same class I molecule. Proc. Natl. Acad. Sci. USA 87, 2137-2141 (1990).
24. Luescher, I.F. et al. CD8 modulation of T-cell antigen receptor-ligand interactions on living cytotoxic T lymphocytes. Nature 373, 353-356 (1995).
25. Garcia, K.C. et al. CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes. Nature 384, 577-581 (1996).
26. Gao, G.F. et al. Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2. Nature 387, 630-634 (1997).
27. Garboczi, D.N. et al. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384, 134-141 (1996).
28. Wyer, J.R. et al. T Cell Receptor and Coreceptor CD8αα Bind Peptide-MHC Independently and with Distinct Kinetics. Immunity 10, 219-225 (1999).
29. Jameson, S.C., Carbone, F.R. & Bevan, M.J. Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells. J. Exp. Med. 177, 1541-1550 (1993).
30. De Magistris, M.T. et al. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68, 625-634 (1992).
31. Price, D.A. et al. The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection. J. Mol. Med. 76, 699-708 (1998).
32. Sewell, A.K., Harcourt, G.C., Goulder, P.J., Price, D.A. & Phillips, R.E. Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides. Eur. J. Immunol. 27, 2323-2329 (1997).
33. Bertoletti, A. et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369, 407-410 (1994).
34. Klenerman, P. et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 369, 403-407 (1994).
35. Allen, P.M. & Zinkernagel, R.M. Promethean viruses? Nature 369, 355-356 (1994).
36. Preckel, T., Grimm, R., Martin, S. & Weltzien, H.U. Altered hapten ligands antagonize trinitrophenyl-specific cytotoxic T cells and block internalization of hapten-specific receptors. J. Exp. Med. 185, 1803-1813 (1997).
37. Purbhoo, M.A. et al. Copresentation of natural HIV-1 agonist and antagonist ligands fails to induce the T cell receptor signaling cascade. Proc. Natl. Acad. Sci. USA 95, 4527-4532 (1998).
38. Viola, A. & Lanzavecchia, A. T cell activation determined by T cell receptor number and tunable thresholds. Science 273, 104-106 (1996).
39. Cerundolo, V., Tse, A.G., Salter, R.D., Parham, P. & Townsend, A. CD8 independence and specificity of cytotoxic T lymphocytes restricted by HLA-Aw68.1. Proc. R. Soc. Lond. B. Biol. Sci. 244, 169-177 (1991).
40. Lyons, D.S. et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 5, 53-61 (1996).
41. Kessler, B.M., Bassanini, P., Cerottini, J.C. & Luescher, I.F. Effects of epitope modification on T cell receptor-ligand binding and antigen recognition by seven H-2Kd-restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. J. Exp. Med. 185, 629-640 (1997).
42. Hampl, J., Chien, Y.H. & Davis, M.M. CD4 augments the response of a T cell to agonist but not to antagonist ligands. Immunity 7, 379-385 (1997).
43. Davis, M.M. et al. Ligand recognition by alphabeta T cell receptors. Annu. Rev. Immunol. 16, 523-544 (1998).
44. Boniface, J.J. et al. Initiation of signal transduction through the T cell receptor requires the peptide multivalent engagement of MHC ligands. Immunity 9, 459-466 (1998).
45. Choksi, S., Jameson, B.A. & Korngold, R. A structure-based approach to designing synthetic CD8alfa peptides that can inhibit cytotoxic T-lymphocyte reponses. Nature Med. 4, 309-314 (1998).
46. Giblin, P., Ledbetter, J.A. & Kavathas, P. A secreted form of the human lymphocyte cell surface molecule CD8 arises from alternative splicing. Proc. Natl. Acad. Sci. USA 86, 998-1002 (1989).
47. Ho, A.D. et al. Plasma levels of soluble CD8 antigen and interleukin-2 receptor antigen in patients with hairy cell leukemia, relationship with splenectomy and with clinical response to therapy. Leukemia 3, 718-723 (1989).
48. Zielinski, C.C., Pesau, B. & Muller, C. Soluble interleukin-2 receptor and soluble CD8 antigen in active rheumatoid arthritis. Clin. Immunol. Immunopathol. 57, 74-82 (1990).
49. Maimone, D. & Reder, A.T. Soluble CD8 levels in the CSF and serum of patients with multiple sclerosis. Neurology 41, 851-854 (1991).
50. Linker Israeli, M. et al. Elevated in vivo and in vitro secretion of CD8-alpha molecules in patients with systemic lupus erythematosus. J. Immunol. 152, 3158-3167 (1994).
51. Agostini, C. et al. Increased levels of soluble CD8 molecule in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. Clin. Immunol. Immunopathol. 50, 146-153 (1989).
52. Reinherz, E.L. & Schlossman, S.F. The differentiation and function of human T lymphocytes. Cell 19, 821-827 (1980).
53. Price, D.A. et al. Antigen specific release of beta-chemokines by anti-HIV1 cytotoxic T lymphocytes. Curr. Biol. 8, 355-358 (1998).
54. Cobbold, S.P., Qin, S., Leong, L.Y., Martin, C. & Waldmann, H. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol. Rev. 129, 165-201 (1992).